Centiva Capital’s Aquestive Therapeutics AQST Stock Holding History

Centiva Capital’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-63,951	Closed	-$212K	–	1094
2025 Q2	$212K	Buy	+63,951	New	+$183K	﹤0.01%	1315

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Centiva Capital's AQST Position: Q3 2025 in Review

Centiva Capital sold out of Aquestive Therapeutics (AQST) in Q3 2025, closing a stake of 63,951 shares — an estimated $212K sold.

Centiva Capital first reported a position in AQST in Q2 2025 and held it in 1 quarter. The position peaked at $212K in Q2 2025. 152 funds tracked by Wall St. Rank hold AQST as of Q3 2025.

Centiva Capital reported no remaining Aquestive Therapeutics position as of Q3 2025 after selling out during the quarter.
Centiva Capital sold 63,951 Aquestive Therapeutics shares in Q3 2025, an estimated $212K.
Centiva Capital first reported a position in Aquestive Therapeutics in Q2 2025 and held it in 1 quarter.
Centiva Capital's Aquestive Therapeutics position peaked at $212K in Q2 2025.
152 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2025.

Based on Centiva Capital's 13F filing for Q3 2025, filed 14 Nov 2025.